{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:25:26Z","timestamp":1777465526377,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","academicpedsjnl.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Pediatrics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.acap.2016.03.011","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T21:37:23Z","timestamp":1459892243000},"page":"508-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Challenges and Promises of Pediatric Psychopharmacology"],"prefix":"10.1016","volume":"16","author":[{"given":"Lisa L.","family":"Giles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Richard","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acap.2016.03.011_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4088\/JCP.11r07064","article-title":"Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics","volume":"72","author":"Correll","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/wps.20028","article-title":"Pediatric psychopharmacology: too much or too little?","volume":"12","author":"Rapoport","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1542\/peds.2014-1581","article-title":"Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety","volume":"136","author":"Southammakosane","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","article-title":"National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996\u20132007","volume":"49","author":"Comer","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamapediatrics.2013.431","article-title":"Medication use in US youth with mental disorders","volume":"167","author":"Merikangas","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.acap.2016.03.011_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1542\/peds.2014-2260","article-title":"Antipsychotic medication prescribing in children enrolled in Medicaid","volume":"135","author":"Rettew","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib7","doi-asserted-by":"crossref","first-page":"e1178","DOI":"10.1542\/peds.2015-0807","article-title":"Outpatient visits and medication prescribing for US children with mental health conditions","volume":"136","author":"Anderson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ambp.2007.10.006","article-title":"Do pediatricians think they are responsible for identification and management of child mental health problems? Results of the AAP periodic survey","volume":"8","author":"Stein","year":"2008","journal-title":"Ambul Pediatr"},{"key":"10.1016\/j.acap.2016.03.011_bib9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","article-title":"ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"128","author":"Wolraich","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children With ADHD","volume":"56","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cap.2007.0068","article-title":"Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit\/Hyperactivity Disorder Treatment Study (PATS)","volume":"17","author":"Abikoff","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CHI.0b013e31819c23d0","article-title":"The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study","volume":"48","author":"Molina","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.chi.0000235077.32661.61","article-title":"Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD","volume":"45","author":"Greenhill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib15","first-page":"678","article-title":"Using meta-analysis to compare the efficacy of medications for attention-deficit\/hyperactivity disorder in youths","volume":"34","author":"Faraone","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.acap.2016.03.011_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaac.2011.07.018","article-title":"Cardiovascular risk of stimulant treatment in pediatric attention-deficit\/hyperactivity disorder: update and clinical recommendations","volume":"50","author":"Hammerness","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14740338.2015.1011620","article-title":"Attention-deficit\/hyperactivity disorder treatment: what are the long-term cardiovascular risks?","volume":"14","author":"Hammerness","year":"2015","journal-title":"Exp Opin Drug Saf"},{"key":"10.1016\/j.acap.2016.03.011_bib19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/appi.ajp.2009.09040472","article-title":"Sudden death and use of stimulant medications in youths","volume":"166","author":"Gould","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/DBP.0b013e31318185dc14","article-title":"American Academy of Pediatrics\/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: 2008","volume":"29","year":"2008","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.acap.2016.03.011_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S1047951111000928","volume":"22","author":"Hamilton","year":"2012","journal-title":"Cardiol Young"},{"key":"10.1016\/j.acap.2016.03.011_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.chi.0000215326.51175.eb","article-title":"The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit\/hyperactivity disorder","volume":"45","author":"Pliszka","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004583-200102000-00013","article-title":"Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA","volume":"40","author":"Vitiello","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"suppl 2","key":"10.1016\/j.acap.2016.03.011_bib24","first-page":"1","article-title":"Mental health surveillance among children\u2014United States, 2005\u20132011","volume":"62","author":"Perou","year":"2013","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.acap.2016.03.011_bib25","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2016.03.011_bib26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acap.2016.03.011_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-4-1","article-title":"Child\/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods","volume":"4","author":"Compton","year":"2010","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.acap.2016.03.011_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2016.03.011_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1176\/appi.ajp.2009.08101606","article-title":"Clinical messages from the Treatment for Adolescents With Depression Study (TADS)","volume":"166","author":"March","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jama.299.8.901","article-title":"Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial","volume":"299","author":"Brent","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2016.03.011_bib31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1176\/appi.ajp.2009.08101606","article-title":"The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up","volume":"166","author":"March","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib32","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials","volume":"297","author":"Bridge","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2016.03.011_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","article-title":"A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder","volume":"54","author":"Strawn","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/da.22329","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"32","author":"Strawn","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.acap.2016.03.011_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaac.2011.09.019","article-title":"Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder","volume":"51","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/cap.2009.0115","article-title":"Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial","volume":"20","author":"Robb","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib37","first-page":"CD002317","article-title":"Tricyclic drugs for depression in children and adolescents","volume":"6","author":"Hazell","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acap.2016.03.011_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.psc.2014.05.006","article-title":"Pharmacological treatment of obsessive-compulsive disorder","volume":"37","author":"Pittenger","year":"2014","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.acap.2016.03.011_bib39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/chi.0b013e318145ae1c","article-title":"Practice parameter for the assessment and treatment of children and adolescents with depressive disorders","volume":"46","author":"Birmaher","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.chi.0000246070.23695.06","article-title":"Practice\u00a0parameter for the assessment and treatment of children and adolescents with anxiety disorders","volume":"46","author":"Connolly","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/chi.0b013e31804a859b","article-title":"Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder","volume":"46","author":"Hughes","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib43","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1542\/peds.2006-1395","article-title":"Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management","volume":"120","author":"Cheung","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.chi.0000242240.69678.c4","article-title":"Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder","volume":"46","author":"McClellan","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cap.2010.0084","article-title":"Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder","volume":"21","author":"Findling","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1542\/peds.2015-0743","article-title":"Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study","volume":"136","author":"Findling","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2016.03.011_bib47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.chi.0000194569.70912.a7","article-title":"Open-label lithium for the treatment of adolescents with bipolar depression","volume":"45","author":"Patel","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.psychres.2009.01.022","article-title":"Pharmacological response in juvenile bipolar disorder subtypes: a naturalistic retrospective examination","volume":"177","author":"Masi","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.acap.2016.03.011_bib49","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaac.2011.05.011","article-title":"Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis","volume":"50","author":"Liu","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archgenpsychiatry.2011.1508","article-title":"A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents","volume":"69","author":"Geller","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib51","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaac.2015.09.015","article-title":"Treatment of early-age mania: outcomes for partial and nonresponders to initial treatment","volume":"54","author":"Walkup","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaac.2015.09.016","article-title":"Depression and suicidality outcomes in the treatment of early age mania study","volume":"54","author":"Salpekar","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.acap.2016.03.011_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00213-006-0537-6","article-title":"Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents","volume":"191","author":"Ipser","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.acap.2016.03.011_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371506000203","volume":"60","author":"Pringsheim","year":"2015","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/cap.2013.0121","article-title":"Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review","volume":"24","author":"Shon","year":"2014","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jaac.2015.09.017","article-title":"Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study","volume":"54","author":"Findling","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib58","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/NDT.S68951","article-title":"The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode","volume":"10","author":"Findling","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.acap.2016.03.011_bib59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.chi.0000159151.75345.20","article-title":"A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder","volume":"44","author":"Delbello","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib60","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1176\/ajp.2006.163.7.1179","article-title":"A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents","volume":"163","author":"Wagner","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-006-0569-y","article-title":"Psychopharmacology of pediatric bipolar disorder: a review","volume":"191","author":"Smarty","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.acap.2016.03.011_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.acap.2016.03.011_bib63","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004583-200302000-00008","article-title":"Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II","volume":"42","author":"Pappadopulos","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"suppl 6","key":"10.1016\/j.acap.2016.03.011_bib65","first-page":"12","article-title":"Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics","volume":"65","author":"DelBello","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/cap.2013.0094","article-title":"Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications","volume":"24","author":"Burcu","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib67","first-page":"CD009582","article-title":"Atypical antipsychotics for psychosis in adolescents","volume":"10","author":"Kumar","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acap.2016.03.011_bib68","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib69","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib70","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaac.2015.09.007","article-title":"Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder","volume":"54","author":"Findling","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/YCO.0000000000000132","article-title":"An update on pharmacotherapy for autism spectrum disorder in children and adolescents","volume":"28","author":"Ji","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib72","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib73","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib74","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am J\u00a0Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaac.2013.09.022","article-title":"What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit\/hyperactivity disorder?","volume":"53","author":"Aman","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib76","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaac.2014.05.008","article-title":"Risperidone added to parent training and stimulant medication: effects on attention-deficit\/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression","volume":"53","author":"Gadow","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib77","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.acap.2016.03.011_bib79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12888-015-0504-z","article-title":"Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2015","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib80","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40265-014-0254-0","article-title":"The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview","volume":"74","author":"Budman","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.acap.2016.03.011_bib81","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.acap.2016.03.011_bib82","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.acap.2016.03.011_bib83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acap.2016.03.011_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaac.2014.10.002","article-title":"Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials","volume":"54","author":"Jensen","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.acap.2016.03.011_bib85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale","volume":"173","author":"Lane","year":"1985","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.acap.2016.03.011_bib86","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/CHI.0b013e3181ae0a08","article-title":"Practice parameter on the use of psychotropic medication in children and adolescents","volume":"48","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Academic Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876285916300997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876285916300997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T04:46:07Z","timestamp":1567745167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876285916300997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1876285916300997"],"URL":"https:\/\/doi.org\/10.1016\/j.acap.2016.03.011","relation":{},"ISSN":["1876-2859"],"issn-type":[{"value":"1876-2859","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and Promises of Pediatric Psychopharmacology","name":"articletitle","label":"Article Title"},{"value":"Academic Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acap.2016.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 by Academic Pediatric Association","name":"copyright","label":"Copyright"}]}}